Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Upstream Bio (UPB) Cost of Revenue (2024 - 2025)

Upstream Bio has reported Cost of Revenue over the past 2 years, most recently at $8.3 million for Q4 2025.

  • Quarterly results put Cost of Revenue at $8.3 million for Q4 2025, up 202.25% from a year ago — trailing twelve months through Dec 2025 was $23.0 million (up 243.17% YoY), and the annual figure for FY2025 was $23.0 million, up 249.74%.
  • Cost of Revenue for Q4 2025 was $8.3 million at Upstream Bio, up from $2.5 million in the prior quarter.
  • Over the last five years, Cost of Revenue for UPB hit a ceiling of $10.0 million in Q2 2025 and a floor of $351000.0 in Q1 2024.